NeuroBo Pharmaceuticals (NASDAQ:NRBO) (NASDAQ: NRBO) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel small‐molecule therapies for neurological disorders characterized by motor dysfunction and spasticity. Headquartered in Newton, Massachusetts, NeuroBo leverages its proprietary chemistry platform to generate compounds that modulate inhibitory and excitatory neurotransmission, aiming to restore balance in central nervous system circuits. The company’s scientific approach is grounded in decades of research into ion channel modulation and receptor pharmacology, with a robust preclinical portfolio that supports advancement of multiple candidates toward human studies.
The company’s lead therapeutic candidate, NB-01, is designed to amplify GABAergic signaling to reduce spasticity in conditions such as cerebral palsy and post‐stroke spasticity. NB-01 has completed initial toxicology and pharmacokinetic evaluations, paving the way for planned Phase 1 trials. In parallel, NeuroBo is advancing additional pipeline assets—NB-02 and NB-03—targeting hyperkinetic movement disorders, including certain forms of parkinsonism and dystonia. These programs benefit from the company’s integrated medicinal chemistry, in vitro screening, and in vivo efficacy models, with a focus on oral formulations suitable for chronic administration.
Founded in 2017, NeuroBo transitioned to the public markets in 2021 via a NASDAQ listing, raising capital to accelerate its clinical and preclinical programs. The company maintains strategic collaborations with contract research organizations across North America and Europe, supporting IND-enabling studies and GMP manufacturing. NeuroBo’s research efforts also extend to exploring biomarkers for patient stratification and treatment response, underscoring its commitment to precision medicine in neurology. The organization’s operational footprint spans its Massachusetts headquarters and joint laboratories in the United Kingdom, facilitating access to specialized neuroscience expertise.
Leadership at NeuroBo is spearheaded by Richard Maas, President and Chief Executive Officer, who brings over 25 years of drug development experience from both large‐cap and emerging biopharmaceutical companies. Under his guidance, the company has built a multidisciplinary team of neuroscientists, clinical development experts, and regulatory specialists. Complementing the executive team is a board of directors composed of seasoned industry veterans and academic thought leaders, ensuring strategic oversight and scientific rigor as NeuroBo progresses toward its mission of delivering first‐in‐class treatments for debilitating neurological conditions.
